Relevant studies were identified from Medline, the Web of Science, and additional references cited within the articles retrieved. Keywords were “HIV” or “AIDS”, cross-referenced with “cost,” “expenditure,” or “utilisation.” Dates for inclusion were between January 1996 and June 2005. Abstracts were not considered.
ReviewThe direct costs of HIV/AIDS care
Introduction
AIDS is characterised by the progressive destruction of a person's immune system and is the late and most serious stage of HIV infection. Over the past two decades, the epidemic has become a major challenge to health-care systems, with more than 20 million people dying from HIV/AIDS and a further 40·3 million people worldwide estimated to be infected in 2005.1 Recent advances in treatment, especially the use of potent combinations of nucleoside reverse transcriptase inhibitors, protease inhibitors, and non-nucleoside reverse transcriptase inhibitors (referred to as highly active antiretroviral therapy, or HAART), have resulted in dramatic reductions in the rates of HIV disease progression, opportunistic infections, hospital admissions, and deaths.2, 3, 4, 5 In developed countries, the remarkable success of HAART has also altered the use of health-care resources for HIV-infected patients, with the nature of treatment shifting from inpatient hospital admissions to outpatient care and greater use of medications in the outpatient setting.6 Furthermore, HIV prevalence is increasing in western countries as a consequence of falling death rates.1, 7, 8
These changes have occurred against a background of little empirical evidence about the direct costs of treating HIV-infected people in terms of per-person annual expenditures and lifetime costs,9, 10 the implications on the cost of using different treatment strategies,11, 12 or the extent to which costs vary by stage of HIV infection.13 Information on the direct costs of treatment is important since it provides a basis for health planners to allocate budgets or reimburse specific categories of expenditures. It also enables policymakers, when faced with changes in prevalence—eg, that currently occurring with the spread of HIV infection among injection drug users14—to make more informed choices between programmes. To optimally allocate scarce economic resources to prevention and treatment programmes, planners require accurate, up-to-date estimates of the direct costs of treatment.15, 16, 17 Although economic evaluation is an important approach for establishing priorities for health interventions,6, 18, 19 in practice this type of evaluation has been of limited value in HIV/AIDS because of the paucity of accurate cost data.9
The purpose of this review is to identify published estimates of the direct medical costs, including hospital inpatient, outpatient, and medication costs for treating HIV-infected individuals after HAART was introduced into routine clinical practice, to determine the extent to which these estimates can be validly compared, and to make such comparisons where possible. In cases where meaningful comparisons are not possible, we explain why this is the case. We also discuss the implications for future research in this area.
Section snippets
Methods
To be included, studies had to meet pre-specified criteria for information content. We identified studies that included an original estimate of the mean monthly or annual direct medical costs of treating an HIV-infected individual. We included studies from English language peer-reviewed published work that provided enough detail to allow meaningful comparisons by explicitly describing the study period, location and population (demographic and clinical distributions), types of treatments, data
Results
Of 543 titles initially identified, 92 were flagged as potentially relevant. Based on the abstracts, full versions of 33 were obtained. Another six relevant publications were cited within retrieved articles. After reviewing each study, nine were judged to meet the inclusion criteria.
Table 1 summarises the major characteristics of each study. The studies ranged in the number of included people from 7421 to 5708,22 and one study was considered population based23 because it included all patients
Discussion
We found substantial variation in studies reporting the total and component-specific direct medical costs of treating HIV-infected individuals in the HAART era. Valid comparisons of the estimates from the nine studies reviewed were not possible because of differences in the specific components included, the heterogeneous nature of the study populations in terms of disease stage, the sources and methods used to estimate unit costs, and the level of aggregation at which results were reported.
Search strategy and selection criteria
References (36)
- et al.
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Lancet
(1999) - et al.
The treatment and care costs of people with HIV-infection or AIDS: development of a standardized cost framework for Europe
Health Policy
(1993) AIDS epidemic update: December 2005
- et al.
Natural history of HIV infection in the era of combination antiretroviral therapy
AIDS
(1999) - et al.
Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
AIDS
(1997) - et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
N Engl J Med
(1998) - et al.
Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy
Antivir Ther
(2002) Looking forward: focussing the response. Canada's report on HIV/AIDS 2003
Global summary of the HIV and AIDS epidemic in 2005
- et al.
The cost of HIV treatment and care. A global review
Pharmacoeconomics
(2001)
HIV patients in the HCUP database: a study of hospital utilization and costs
Inquiry
Hospital and outpatient health services utilization among HIV-infected patients in care in 1999
J Acquir Immune Defic Syndr
Impact of practice changes on an antiretroviral budget in an HIV care program
Disease Management and Health Outcomes
Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic
AIDS
Priorities for action in managing the epidemics. HIV/AIDS in BC: 2003–2007
Economic evaluation of HIV prevention programs
Annu Rev Public Health
Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
J Acquir Immune Defic Syndr Hum Retrovirol
Cited by (69)
A Cost-of-Illness Study of Patients with HIV/AIDS in Bogotá, Colombia
2017, Value in Health Regional IssuesCitation Excerpt :We observed no significant difference between CDC classifications and higher costs for CDC stage 1 or for CD4 cell count. This result contradicts international findings that suggest that individuals at more advanced stages of the disease incur higher costs [22,23,25]. The small sample size of our study (especially in CDC stages 1 and 2) could explain this nonsignificant result.
Estimation of the Direct Cost of HIV-Infected Patients in Greece on an Annual Basis
2014, Value in Health Regional IssuesCitation Excerpt :As a matter of fact, the aforestated studies used a different approach for the estimation of HIV infection’s direct cost. As a result, comparing the findings of the different studies seems quite challenging; however, some general conclusions can certainly be drawn [22,23]. The present survey seems to be in line with the European studies regarding the overall results; nonetheless, some differences can be distinguished.
Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain
2013, Enfermedades Infecciosas y Microbiologia ClinicaA comparative analysis of outpatient costs in HIV treatment programs
2012, Revista da Associacao Medica BrasileiraWhat are the drivers of high-cost HIV patients?
2021, International Journal of STD and AIDS